30 August 2023>: Clinical Research
An Examination of Infection Incidence and Management in Systemic Lupus Erythematosus Patients: A Five-Year Review from a Saudi Arabian Center
Noha K. Khalil 1ABDF* , Fahidah Alenzi 2EF** , Mohammed A. Omair 3ACDF , Ibrahim Almaghlouth 3CD , Mansour Altuwaijri 4AB , Mazen Barri 1AF , Rakan M. Alqahtani 5AB , Abdulaziz Alrabiah 6AB , Ali Alhijji 1ABDOI: 10.12659/MSM.941277
Med Sci Monit 2023; 29:e941277
Table 1 Patients’ baseline characteristics in evaluation and treatment flow of 74 SLE patients with infections.
N (%) | |
---|---|
Male | 63 (85.1%) |
Female | 11 (14.9%) |
37.2±14.5 | |
8.27±7.75 | |
Underweight | 6 (08.1%) |
Normal | 32 (43.2%) |
Overweight | 18 (24.3%) |
Obese class I | 12 (16.2%) |
Obese class II | 3 (4.1%) |
Obese class III | 3 (4.1%) |
Malignancy | 4 (5.4%) |
APS | 11 (14.9%) |
Sjögren syndrome | 1 (1.4%) |
Previous sepsis | 23 (31.1%) |
Prednisolone | 56 (75.7%) |
Hydroxychloroquine | 59 (79.7%) |
Rituximab | 4 (05.4%) |
Cyclophosphamide | 6 (8.1%) |
MMF | 30 (40.5%) |
Tacrolimus | 1 (1.4%) |